Shamburg News · 8-K filed Nov 16, 2026, 4:35 PM EST

Lakewood-Amedex Biotherapeutics Receives Nasdaq Delisting Notice Over Bid Price Rule

LABT · Lakewood-Amedex Biotherapeutics Inc.

  • Delisting
  • Materiality: high

On November 10, 2026, Lakewood-Amedex Biotherapeutics Inc. received a Nasdaq Listing Qualifications letter stating its common stock closed below $1.00 per share for 30 consecutive business days from September 29, 2026 through November 9, 2026. Because the company effected a 1-for-10 reverse stock split on June 22, 2026, within the prior one-year period, it is not eligible for a compliance period and Nasdaq has determined to delist its securities. Trading is scheduled to be suspended at the opening of business on November 19, 2026 unless the company requests a hearing by November 17, 2026, which the company intends to do.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 3.01, 9.01, accession 0001213900-26-120724.

Written from the filing by Shamburg Markets. Figures are as reported by the company.